YHC2133

YHC2133 is a preclinical biologic candidate being developed through a collaboration between Yuhan Corporation and ABL Bio for the treatment of neurodegenerative brain diseases. While specific molecular targets remain proprietary, the program leverages ABL Bio's expertise in bispecific antibody engineering and blood-brain barrier (BBB) penetration technologies, such as the 'Grabody-B' platform. This platform is designed to facilitate the transport of therapeutic antibodies across the BBB to modulate disease-relevant pathways within the central nervous system. The partnership between Yuhan and ABL Bio aims to address significant unmet medical needs in the neurodegeneration space, targeting conditions where effective drug delivery to the brain has historically been a major challenge.